Cargando…
Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts
OBJECTIVES: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the development...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Oral and Maxillofacial Surgeons
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279973/ https://www.ncbi.nlm.nih.gov/pubmed/25551094 http://dx.doi.org/10.5125/jkaoms.2014.40.6.291 |
_version_ | 1782350790731497472 |
---|---|
author | Kwon, Taek-Kyun Song, Jae-Min Kim, In-Ryoung Park, Bong-Soo Kim, Chul-Hoon Cheong, In-Kyo Shin, Sang-Hun |
author_facet | Kwon, Taek-Kyun Song, Jae-Min Kim, In-Ryoung Park, Bong-Soo Kim, Chul-Hoon Cheong, In-Kyo Shin, Sang-Hun |
author_sort | Kwon, Taek-Kyun |
collection | PubMed |
description | OBJECTIVES: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the development of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling. MATERIALS AND METHODS: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 µM alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. RESULTS: Cell viability was decreased to 82.75%±1.00% by alendronate and then increased to 110.43%±1.35% after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly affected by rhBMP-2. CONCLUSION: rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression. |
format | Online Article Text |
id | pubmed-4279973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The Korean Association of Oral and Maxillofacial Surgeons |
record_format | MEDLINE/PubMed |
spelling | pubmed-42799732014-12-30 Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts Kwon, Taek-Kyun Song, Jae-Min Kim, In-Ryoung Park, Bong-Soo Kim, Chul-Hoon Cheong, In-Kyo Shin, Sang-Hun J Korean Assoc Oral Maxillofac Surg Original Article OBJECTIVES: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the development of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling. MATERIALS AND METHODS: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 µM alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. RESULTS: Cell viability was decreased to 82.75%±1.00% by alendronate and then increased to 110.43%±1.35% after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly affected by rhBMP-2. CONCLUSION: rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression. The Korean Association of Oral and Maxillofacial Surgeons 2014-12 2014-12-26 /pmc/articles/PMC4279973/ /pubmed/25551094 http://dx.doi.org/10.5125/jkaoms.2014.40.6.291 Text en Copyright © 2014 The Korean Association of Oral and Maxillofacial Surgeons. All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kwon, Taek-Kyun Song, Jae-Min Kim, In-Ryoung Park, Bong-Soo Kim, Chul-Hoon Cheong, In-Kyo Shin, Sang-Hun Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts |
title | Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts |
title_full | Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts |
title_fullStr | Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts |
title_full_unstemmed | Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts |
title_short | Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts |
title_sort | effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279973/ https://www.ncbi.nlm.nih.gov/pubmed/25551094 http://dx.doi.org/10.5125/jkaoms.2014.40.6.291 |
work_keys_str_mv | AT kwontaekkyun effectofrecombinanthumanbonemorphogeneticprotein2onbisphosphonatetreatedosteoblasts AT songjaemin effectofrecombinanthumanbonemorphogeneticprotein2onbisphosphonatetreatedosteoblasts AT kiminryoung effectofrecombinanthumanbonemorphogeneticprotein2onbisphosphonatetreatedosteoblasts AT parkbongsoo effectofrecombinanthumanbonemorphogeneticprotein2onbisphosphonatetreatedosteoblasts AT kimchulhoon effectofrecombinanthumanbonemorphogeneticprotein2onbisphosphonatetreatedosteoblasts AT cheonginkyo effectofrecombinanthumanbonemorphogeneticprotein2onbisphosphonatetreatedosteoblasts AT shinsanghun effectofrecombinanthumanbonemorphogeneticprotein2onbisphosphonatetreatedosteoblasts |